라이센싱을위한, Cortellis 최적의활용법 › ... › 20190627_CDI-Webinar.pdf · 6 •...
Transcript of 라이센싱을위한, Cortellis 최적의활용법 › ... › 20190627_CDI-Webinar.pdf · 6 •...
라이센싱을위한, Cortellis 최적의활용법
Cortellis Deal Intelligence
이경미
2019. 6. 27
1
Agenda
Cortellis 소개
라이센싱을위한 CCI 활용법?
Live Demo
Summary
2.
3.
4.
5.
라이센싱트렌드1.
Agenda
Cortellis 소개
라이센싱을위한 CCI 활용법?
Live Demo
Summary
2.
3.
4.
5.
라이센싱트렌드1.
4** Funding $6.0 (2017), $14.9 (2018); Commercial $24.0, $2.0; Service <$0.1, $0.2; Other (royalty buy-out, spin-out, settlement) $4.4, $1.2.
2018 Vs 2017: 글로벌거래트렌드
M&A, 482 M&A, 449
Licenses, 1811
Licenses, 1658
Asset Purch, 210 Asset Purch,
184
Funding, 941
Funding, 734
Commercial, 563
Commercial, 560
Service, 465
Service, 376
Other, 50
Other, 53
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
2017 2018
Volume
4014
4522
M&A, $256M&A, $276
Licenses, $88
Licenses, $111
Asset Purch, $33
Asset Purch, $22
$0
$50
$100
$150
$200
$250
$300
$350
$400
$450
2017 2018
Announced $ billion
$428 B
$392 B
**
**
Source: Cortellis Deal Intelligence 2019
US FDA 승인약물: 거래를통한혁신추진
5Insert footer
All NME approvals Oncology NME approvals
US FDA CDER NME approvals resulting from licensing/acquisition (2010-2018)
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
2010 2011 2012 2013 2014 2015 2016 2017 2018*
Source: FDA, Clarivate Analytics analysis
6
• Covers key transactions types, M&As, Licenses/joint ventures, Research-only deals, and Other (Asset Purchases, Equity Stakes, Spin-outs), with identifiable therapeutic focus areas.• Covers all technologies.
• Not shown: Other, Genitourinary, Musculoskeletal, Toxicity, Unknown and Not Applicable therapy area deals. • Companies are the top 30 pharmas as ranked by 2017 revenues.
글로벌제약사: 거래를통한질환포트폴리오확장또는강화
Number of buy-side transactions by therapy area for top pharma dealmakers
J&J
Me
rck
No
vart
is A
G
Ro
che
Eli L
illy
& C
o
Take
da
San
ofi
AZ
No
vo N
ord
isk
Pfi
zer
BI
Ab
bV
ie
Gil
ead
Ast
ell
as
Bio
gen
Me
rck
KG
aA
Ce
lge
ne
Dai
ich
i San
kyo
GSK
Am
gen
Bay
er
BM
S
Myl
an
Ots
uka
All
erg
an
CSL
Shir
e
UC
B
Teva
TOTA
L
Oncology 9 17 8 12 2 3 3 9 6 4 5 5 3 7 1 6 1 2 1 1 3 108
Neuroscience 6 1 3 3 3 3 1 1 1 2 1 7 3 2 1 2 40
Immuno/Inflam 2 1 4 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 23
Endo/Met 2 3 1 8 1 1 16
Infection 1 1 1 2 5 1 1 2 1 1 16
Diversified 1 3 1 2 3 1 1 1 13
GI 2 1 4 1 1 9
Dermatology 3 1 1 5
Hematology 1 2 1 1 5
Ophthalm 3 1 1 5
Respiratory 1 1 1 1 1 5
Cardiology 1 2 1 4
Total 27 20 20 18 14 14 13 12 12 12 9 8 8 7 7 7 6 6 6 3 3 3 3 3 2 2 2 2 0 222
Source: Cortellis Deal Intelligence 2019
Agenda
Cortellis 소개
라이센싱을위한 CCI 활용법?
Live Demo
Summary
2.
3.
4.
5.
라이센싱트렌드1.
: DATABASE
THE COMPLETE SOLUTION FOR DRUG LIFECYCLE
8
Research
Market Landscape
Clinical
Regulatory
Post-Launch
CORTELLIS CLINICAL
TRIALS INTELLIGENCE
CORTELLIS
REGULATORY
INTELLIGENCE
CORTELLIS
COMPETITIVE
INTELLIGENCE
CORTELLIS
DEAL
INTELLIGENCE
IPD
BIOWORLDNEWPORT THOMSON
INNOVATION
METACORE INTEGRITY/
DRA
WOS
Competitive Intelligence Clinical Trials Intelligence Regulatory Intelligence Deal Intelligence
• 의약품 (시판&개발파이프라인), 회사, 임상, 거래, 특허, 논문, 학회자료등주요 10가지내용
• 질환별, 기전별, 기술별, 회사별시장분석도구
• Clinicaltrials.gov이외의각국인허가/임상기관으로부터정보수집
• 임상시험결과값/부작용값함께제공
• 임상시험기간, 환자수, 지역등에따른 Spot Fire 분석
• 80여개의국가의개별인허가규정비교분석
• Marketing authorization, Pricing & Reimburse, Quality assurance 등약물개발규정포함
• Advanced therapy, Medical device, Bio-similar/generics, Pediatric use, Orphan drugs 등특정규정포함
• 더넓은커버리지 (88,000 deals and 29,000 contracts for CDI)
• Deal term breakdown (upfront, Dev/Reg milestone, Equity)
• M&A거래
• 원본계약서제공, 질환별분석
• Financial summary 제공
9
CORTELLIS : Body of Knowledge
Agenda
Cortellis 소개
라이센싱을위한 CCI 활용법?
Live Demo
Summary
2.
3.
4.
5.
라이센싱트렌드1.
• 공개된거래규모를보기위해, 라이센싱거래검색
• 평균 (Average), 중간값 (Median) 거래규모의확인필요
11
“DEAL VALUE”에집중!
최적의라이센싱을위한 Cortellis의활용법?
12Insert footer
Outlier 확인, 분석에서제외또는포함
최적의라이센싱을위한 Cortellis의활용법?
13Insert footer
지역, 질환, 제품과옵션수와같은주요필드검토.
최적의라이센싱을위한 Cortellis 활용법?
Agenda
Cortellis 소개
라이센싱을위한 CCI 활용법?
Live Demo
Summary
2.
3.
4.
5.
라이센싱트렌드1.
• 거래규모에집중!
✓ 라이센싱검색
: 평균/ 중간값확인
Outlier 제외
지역, 질환및제품/옵션수와같은주요필드확인
• 글로벌제약사의거래트렌드분석
• In Cortellis Deal Intelligence,
✓ 거래규모차트로확인및활용
✓ 분석결과에서 Outlier 확인및제외
✓ 주요필드검토
15Insert footer
Summary
감사합니다.
16
© 2019 Clarivate Analytics. All rights reserved. Republication or redistribution of Clarivate Analytics content, including by framing or similar means, is prohibited without the prior written consent of Clarivate Analytics. Cortellis and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.